Dare Bioscience, Inc.(DARE)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Dare Bioscience, Inc. (DARE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DARE at 10.5/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Dare Bioscience, Inc. reports quarterly revenue of $187.5K, net income of $-3.0M, free cash flow of $-6.9M. Top institutional holders of DARE by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, US BANCORP \DE\, based on the most recent SEC filings. DARE trades on the Nasdaq exchange and files with the SEC under CIK 1401914. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dare Bioscience, Inc. directly from SEC EDGAR.
AI Quality Score
10.5/100
AI Rank
#2,909
Revenue
$187.5K
Net Income
$-3.0M
Free Cash Flow
$-6.9M
DARE key financials by period
Dare Bioscience, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.0M
$-13.4M
—
FY 2024
10-K
$9.8K
$-4.1M
—
FY 2023
10-K
$2.8M
$-30.2M
—
FY 2022
10-K
$10.0M
$-30.9M
—
FY 2016
10-K/A
$766.0K
$-39.3M
-82.3%
FY 2014
10-K/A
$80.0K
$-23.3M
—
Institutions holding DARE
Institutional investors reporting a position in Dare Bioscience, Inc. on SEC Form 13F.
